Keyphrases
Multiple Sclerosis
100%
T Cell Response
100%
Ofatumumab
100%
Response Potential
100%
Migration Potential
100%
T Cells
77%
CD20+ T Cells
55%
Flow Cytometry
22%
B Cells
22%
Relapsing-remitting MS
22%
Autoreactivity
22%
Effector T Cells
22%
Treatment-naïve Patients
22%
Migratory Capacity
22%
Treatment Effect
11%
Relapsing-remitting multiple Sclerosis
11%
Absolute Count
11%
T Cell Depletion
11%
Cellular Compartments
11%
Positive Treatment
11%
Anti-CD20 Antibody
11%
B-cell Depletion
11%
CD20
11%
CD20+
11%
Effector Function
11%
Cell Control
11%
Multiple Patients
11%
Peripheral Leukocytes
11%
Steric Hindrance
11%
Peripheral Immune Cells
11%
CD20+ Cells
11%
In Vitro Blood-brain Barrier Model
11%
Barrier Assay
11%
Direct Treatment Effects
11%
Immunology and Microbiology
Multiple Sclerosis
100%
T Cell
100%
Ofatumumab
100%
CD20
53%
B Cell
20%
Relapsing Remitting Multiple Sclerosis
6%
Immune System
6%
T Cell Depletion
6%
Leukocyte
6%
Blood Brain Barrier
6%
Stereospecificity
6%
CD20 Antibody
6%